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Silver nanoparticles (AgNPs) are promising candidates for fighting drug-resistant 
infections because of their intrinsic antimicrobial effect. The antimicrobial efficacy, shown as a 
result of high-yield design of AgNPs, may inadvertently cause variation in host cells biological 
responses. While many factors affect AgNP efficacy, their surface is exposed to the biological 
environment and thus plays a critical role both in preserving antimicrobial efficacy against 
pathogens, as well as preventing cytotoxicity for host cells. Our approach for controlling 
nanoparticle surface properties is built upon engineering a biomimetic interface that provides a 
competitive advantage. Here, we engineered a fusion protein featuring a silver-binding peptide 
domain (AgBP) to enable self-assembly with green fluorescence protein (GFP) to track assembly. 
Following AgNP functionalization with GFP-AgBP, their antimicrobial properties were evaluated 
in conjunction with their cytotoxic properties. GFP-AgBP binding affinity to AgNPs was evaluated 
using localized surface plasmon resonance. The GFP-AgBP biomimetic interface on AgNP 
surfaces provided sustained antibacterial efficacy at relatively low concentrations based upon 
bacterial growth inhibition assays. As a test model, Streptococcus mutans was chosen as one of 
the common pathogens observed in dental caries. Viability and cytotoxicity measurements in 
fibroblast cells (NIH/3T3) exposed to protein-functionalized AgNPs showed significant 
improvement compared to controls. Biointerface engineering offers promise toward tailoring 
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1. Chapter 1: Background & Significance 
1.1 Background 
1.1.1 Biomaterial-Associated Infections  
The high rates of biomaterial-associated infections and the global healthcare burden 
associated with the increase in drug resistant bacteria have prompted significant efforts to develop 
effective antimicrobial agents.[1, 2], For the oral cavity, infections can occur in approximately 5% 
of implanted dental devices with these infections having broad adverse systemic impact.[3-6] In 
the USA, nearly 300,000 dental implants are placed each year to replace or restore craniofacial 
defects or missing teeth.[7] The high number of craniofacial infection is primarily attributed to poor 
material compatibility, the volatile environment with numerous oral bacteria and the formation of 
an impenetrable biofilm.[8, 9] These biofilms shield the bacteria from shear stresses, traditional 
antibiotics, and native immune responses, while simultaneously allowing some of the bacteria to 
escape and invade new surfaces at remote sites.[1, 10, 11] Antibiotic drugs relied upon to fight 
local and systemic infections are being undermined by bacterial resistance. Further, numerous 
authoritative health institutions have fervently informed the global population about the 
burgeoning threat and imminent health crisis regarding antibiotic resistant bacterial strains.[12-
14] Each year, new antibiotic-resistant bacterial strains are identified and continue to grow at 
much faster rate than the pharmaceutical industry can develop novel antibiotics to combat 
them.[15] There has been an increasing significant effort to develop antimicrobial agents to 





1.1.2 Silver Species: Alternative Antimicrobial Agent 
Innovative approaches to biomaterial design for dental implants have focused on 
mitigating the risk of infection at the implant-tissue interface. Recent approaches are designed to 
coat or functionalize the implant surface with various antimicrobial moieties to create an anti-
infective layer between the implant and native tissue.[11] Numerous antimicrobial moieties and 
device coatings have been clinically approved to combat the persistent and challenging burden 
of infections by either limiting bacterial adhesion or actively killing the bacteria upon direct 
contact.[16]  
Silver species [17-35], metal oxides [36-43], various proteins and peptides [44-52], 
charged polymers [53-59], quaternary ammonium salts (QACs) [60-64], and selenium species 
[65, 66] are among the various agents which have been identified as promising weapons in this 
combat. Silver species and specifically silver nanoparticles (AgNPs), have received significant 
attention due to their distinctive physicochemical and antimicrobial properties. Prior to the 
introduction of antibiotics in the 1940’s, silver was the most important antimicrobial agent in 
medicine, utilized for over six millennia to combat infection.[17] Even though silver has been used 
without any documented cases of bacterial resistance, cellular toxicity reports have triggered 
major safety concerns for AgNPs toward healthy tissue in humans. The antimicrobial efficacy and 
potential cytotoxicity of AgNPs in vitro has been shown to be highly dependent upon many factors 
including, but not limited to, nanoparticle size, concentration, stabilization, charge, or surface 
functionalization properties. The ability to tune and control the biological and biocidal effects is 
critical to determine an optimal compromise between maintaining antimicrobial properties while 
mitigating risk of adverse cytotoxic impacts.  However this process is difficult as the exact 
mechanism by which AgNPs impart an effective antimicrobial properties remains largely unclear, 
although several groups have attempted to elucidate its mechanisms of action.[21]  
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1.1.3 Silver Nanoparticle Mechanisms and Characterization 
A variety of potential mechanisms have been proposed, including silver ion release, cell 
membrane interaction and damage, disruption of both ATP synthesis and DNA replication, 
reactive oxygen species and further free radical generation.[19, 21, 67] Numerous studies have 
shown that the overall bactericidal efficacy is highly dependent upon the size and shape of the 
AgNPs used.[24, 26, 68-72] The general trend observed indicates that smaller size nanoparticles 
exhibit a more potent antimicrobial effect.[28, 72]  
Martinez-Castanon, et al, show that minimum inhibitory concentration (MIC) of AgNPs on 
Staphylococcus aureus strains changes from 7.5 μg/mL to 16.67 μg/mL and eventually to 33.71 
μg/mL as NPs’ size changes from 7 to 29 and to 89 nm, respectively.[26] Most prior work 
performed on size-dependent antimicrobial effect of AgNPs was against Escherichia coli as a test 
bacterial strain. However, with rising interest to the oral microbiome and bacterial related caries 
studies,[73] many groups started to focus on oral pathogens since dental caries remains the most 
prevalent infectious disease of mankind.[74] For one of the most abundant oral pathogens, 
Streptococcus mutans, the size-dependent effect was shown for NPs of 8.4, 16.1, and 98 nm, 
where the MIC changed correspondingly to 102, 146 and 320 μg/mL, respectively.[22] The same 
trend was also recently shown on a different oral pathogen strain, where the smallest size NP’s 
(5nm) was found to have the largest antimicrobial effect.[24] For example, for S. mutans and 
Streptococcus sanguis, an MIC of 100 μg/mL was observed for 5nm AgNPs compared to a MIC 
of 200 μg/mL in the case of 55 nm AgNPs.[23]  
Size dependence of activity may be explained by one mechanisms of AgNP action against 
bacteria, namely, the interaction of the particle with the bacterial cell membrane with the 
consequential reduction in cell membrane permeability and respiration. In this case, the smaller 
size particles have a greater ability to cover a larger area of the membrane, thus having a more 
potent effect on altering vital cellular functions.  
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Silver nanoparticles have also been applied to combat bio-film formation associated with 
dental caries, where they have been evaluated for their cytotoxic effect on local tissue and host 
cell integrity. Size-dependent cytotoxic effects have also been observed by several groups.  
Hernandez-Sierra, et. al., have investigated the cytotoxic effects of AgNPs, sized 10, 20, 
and 80 nm, on local dental tissues, evaluated following exposure times of 1, 3, and 7 days.[23] 
Results indicated that AgNPs 20nm or smaller increased cytotoxicity in both a time and dose 
dependent matter, when compared to 80-100nm-sized AgNPs which did not significantly modify 
the viability of primary human culture cells.[23] Therefore, an optimal AgNP size is dependent 
upon its intended use and application, where a balance must be established to select an Ag 
particle size at which the antimicrobial properties are maintained, while cytotoxic effects to host 
cells are mitigated. AgNPs with a size range of 10–25 nm were reported to be more likely to 
promote cellular apoptosis, as well as increased ROS production, when compared to larger 
AgNPs with a size of 80 nm.[75] Results measuring the cytotoxic effects of 10nm AgNPs on 
epithelial lung cells were shown to be surface-coating independent, when compared to AgNPs 
sized 40 and 75 nm.[71] However, it has been concluded that easier uptake and larger surface 
area for AgNPs can serve to make smaller nanoparticles more toxic.[24] In contrast, a study by 
Arora, et. al., suggested that following the uptake of selected concentrations of NPs sized 7–20 
nm, the antioxidant mechanisms found in eukaryotic cells can prevent further oxidative damage 
from the particles.[76] Another group reported that 200 µM of 20 nm silver nanoparticles did not 
induce cytotoxic effects in human dermal fibroblast cells after incubation for up to 8 hours.[77] 
Interestingly, in another study reported a subsequent apoptosis of a fibroblast cell line treated with 
1-100 nm-sized AgNPs.[78]  
Due to these contradictory reports, it is critical to also investigate surface functionalization 




1.1.4 Silver Nanoparticle Functionalization 
AgNP functionalization and its consequential effect on particle stabilization has been shown 
to alter cytotoxicity.[47] Coating or functionalizing AgNPs surfaces with polymers or biomolecules, 
including proteins, alters AgNP size and properties due to the formation of a coronal structure 
formed upon subsequent contact with biological fluids from host tissues.[3, 44, 47, 50, 79] Hard 
and soft coronal structures and compositions alter the AgNP structure and size and therefore can 
affect the both their innate antimicrobial properties and cellular cytotoxicity.[47, 49] The effects of 
the transient, soft corona layer on AgNP function and cellular uptake have not yet been studied 
in detail due to the inability to accurately distinguish the rapidly exchanging, weakly-bound 
proteins in various biological environments.[79] However, the sustained complex protein corona 
properties have been linked to nanoparticle aggregation and cellular association.[50, 79] 
Agglomeration substantially reduces the antimicrobial capacity of AgNPs, so maintaining a 
dispersed and stable AgNPs population is critical. There is strong evidence that different protein 
components existing in biological environments may compete for the AgNP surface and create a 
secondary protein corona signature. The complex protein corona composition of AgNPs in the 
host cell environment may trigger different biological responses; the biological responses may 
affect cellular and biophysicochemical mechanisms, which are of utmost importance for 
deciphering and addressing the safety concerns associated with the use of AgNPs as 
antimicrobial agents. 
 
1.2  Innovation and Approach 
In the scope of this work, we explore the development of a robust, biomimetic surface 
functionalization approach onto AgNPs using engineered fusion proteins that have the ability to 
self-assemble at the material interface through their genetically engineered silver binding peptide 
tags (AgBP).  
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In our previous work, we have designed a multifunctional fusion protein, which included a 
green fluorescence protein (GFP) and a silver-binding peptide (AgBP), identified using phage 
display technology.[48] We demonstrated that the AgBP tag directs the fusion protein to self-
immobilize selectively onto silver nanoparticle arrays on ferroelectric materials.[80] Herein, we 
explored this approach as a way to fight infection and therefore we investigated he bactericidal 
and cytotoxic effects of the fusion-protein stabilized silver nanoparticles.  
We first investigate the binding strength and stability of the fusion protein to the nanoparticles 
using localized surface plasmon resonance sensing (LSPR). With the notable selective binding 
obtained at the nanoparticle interfacial surface, we next explored the antimicrobial effect of the 
fusion protein coated particles on Steptococcus mutans bacterial strain as one of the common 
pathogen in dental caries. Encouraged with the minimum inhibition concentration obtained with 
relatively low AgNP concentration, we next demonstrated a significant reduction in cytotoxicity 
effects on fibroblasts cells and in addition observed an improved metabolic activity for treated 
cells compared to control AgNPs. The biomimetic surface approach described here could be 
expanded to any other nanoscale material surfaces where specific inorganic binding peptides 
could be engineered into proteins and peptides. This enabling technology builds upon biological 
self-assembly that is driven by molecular recognition of the material surfaces by short peptides. 
This biomimetic interface approach may a way to overcome safety concerns in next generation 









2. Chapter 2: Materials and Methods 
2.1 Production of GFP-AgBP Fusion Protein 
MBP-GFP and MBP-GFP-AgBP proteins were expressed and purified as previously 
described.[48, 81] Briefly, following protein expression, cells were harvested via centrifugation at 
4000 rcf for 30 minutes. Cell pellets were re-suspended in column buffer (20mM Tris-HCl, 200mM 
NaCL, 1mM EDTA, pH 7.4). Cells were disrupted via sonication and cell debris was removed by 
centrifugation. Supernatant was loaded onto a buffer-equilibrated amylose resin column (New 
England Biolabs, NEB) and washed to remove unbound protein. MBP-tagged proteins were 
eluted using column buffer supplemented with 10mM maltose. Pure protein fractions were 
concentrated to 1 mg/ml using Amicon Ultra-15 centrifugal filters (Millipore) and transferred to a 
cleavage buffer (20 mM Tris-HCl, 100 mM NaCl, and 2 mM CaCl2, pH 8.0). 
The MBP tag was enzymatically removed using 30 μl of 1 mg/ml Factor Xa (NEB) added 
to 2.5 mg/ml fusion protein substrate. The reaction was incubated at 16°C overnight under gentle 
agitation. Each fusion protein cleavage mixture was loaded onto a hydroxyapatite (BioRad) 
column equilibrated in 20 mM sodium phosphate and 200 mM NaCl (pH 7.2) buffer.  After maltose 
molecules were washed away, protein samples were eluted with 0.5 M sodium phosphate (pH 
7.2). Hydroxyapatite-eluted protein samples were next loaded onto a regenerated amylose resin 
column. MBP-free protein samples were collected as the flow-through. Protein purity was 
assessed using SDS-PAGE gel electrophoresis.  
 
2.2 Silver Nanoparticle Functionalization 
Stock, citrate-coated silver nanoparticles (AgNPs) sized 20, 40, and 80nm (Ted Pella) 
were diluted to desired concentrations. 40nm AgNPs were selected as the most ideal size for 
detailed analysis, reported herein, following initial experimental results on cellular cytotoxicity and 
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bactericidal efficacy. The stock concentration for the 40nm AgNPs was provided as 0.024 mg/ml 
of silver. AgNPs were incubated with a range of protein concentrations for both GFP and GFP-
AgBP. AgNPs were diluted from the stock in DI water and allowed to mix with protein for 24 hours 
at room temperature with gentle agitation. 
The binding affinity and stability of the engineered bi-functional protein, GFP-AgBP, onto 
AgNPs was studied using localized surface plasmon resonance (LSPR). AgNPs were diluted in 
DI water from the stock to achieve a final concentration of 40 μM. A range of protein 
concentrations of either GFP alone or GFP-AgBP were compared to AgNPs diluted in DI water 
only. LSPR was performed on AgNPs prior to exposure to proteins or water control. Following a 
24 hour incubation time, absorbance spectra were taken to study spectral peak shifts due to 
changes in AgNP size or shape, and again following a wash step. Washes were done for all AgNP 
samples by pelleting via centrifugation for 30 minutes at 3000 rcf. The supernatant was carefully 
collected to remove unbound proteins and AgNPs were then reconstituted in DI water and 
subjected to final LSPR analysis. 
AgNP functionalization for antibacterial and cellular viability studies were performed under 
similar conditions. Stock, citrate-coated 40nm AgNPs were diluted to 2X final concentrations 
desired and incubated with 40 μM GFP-AgBP functional peptide or in water only for 2 hours at 
room temperature with gentle mixing (the 2 hour incubation time was selected following time 
dependent binding analysis, not reported herein). Each sample was then pelleted via 
centrifugation and re-suspended in either BHI media or DMEM media for use in bacterial assays 
or fibroblast cellular viability assays, respectively. 
 
2.3 Antimicrobial Activity Assays 
The antimicrobial activity the GFP-AgBP-functionalized and citrate-coated AgNPs was 
studied in Streptococcus mutans (S. mutans; ATCC 25175) bacterial strain. The lyophilized 
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bacteria were reconstituted in Brain Heart Infusion medium (BHI; BD Difco), consistent with ATCC 
standard protocol, and streaked onto a BHI agar (BD Difco) plate. S. mutans plate was incubated 
for 24 hours at 37°C and in the presence of 5% CO2. Overnight cultures were prepared prior to 
each experiment by inoculating 10 ml of fresh BHI media with a single colony of bacteria and 
incubating for 16 hours. The S. mutans cultures were then diluted and growth was monitored via 
optical density measurements at 600nm on a Cytation3 Imaging Multi-Mode Plate Reader 
(BioTek) until a final concentration of 107 colony forming units (CFU)/ml was reached.  
Bacterial disc diffusion assay was carried to test the antimicrobial effect of nanoparticles. 
BHI agar plates were prepared and stored at 4°C and allowed to acclimate to room temperature 
30 minutes prior to experiments. 106 CFUs of S. mutans were spread onto a pre-prepared BHI 
agar plate using aseptic technique. After 5 minutes, loaded discs were placed into each labeled 
quadrant of the plate. Porous, 30μm polyethylene filter discs were utilized to allow for uninhibited 
AgNP diffusion. Each disc was soaked in desired concentrations of protein-stabilized AgNPs and 
compared to the corresponding concentrations of the stock, citrate-coated AgNPs. A positive 
control of 10 μg/ml Ampicillin (Sigma) in DI water was employed and DI water was used as a 
negative control. Following placement of the discs, S. mutans plates were incubated for 24 hours 
at 37°C with 5% CO2. The average diameter of the inhibition zone around each disc was 
measured using a digital calipers at various angles. The measured disc diameter was subtracted 
from the average zone of inhibition calculated for each treatment to normalize measurements for 
data analysis and representation.  
Duplicate samples were prepared for each AgNP concentration studied. Experiments 




2.4 Cellular Cytotoxicity Assays 
The murine-derived fibroblast cell line NIH/3T3 (ATCC CRL-1658) was used as a 
preliminary model to determine any effects the functionalized AgNPs had on cellular viability and 
cytotoxicity. Culture conditions followed ATCC protocol and previously established methods. 
Briefly, cells were grown at 37°C, supplemented with 5% CO2 in Dulbecco’s Modified Eagle’s 
Medium (DMEM; ATCC 30-2002) containing 10% fetal bovine serum (FBS; Gibco) and 1% 
penicillin-streptomycin (Gibco). Media was changed the day after plating as well as media 
changes every 48 hours, as needed. Cells were sub-cultured at 80% confluency or biweekly with 
0.25% Trypsin-EDTA (Gibco).  
To follow cellular viability, NIH/3T3 cells were first seeded into 96-well plates with black 
side/clear (BrandTech) at 104 cells/well. Following complete cell attachment to plate, media was 
changed and various concentrations of untreated (stock, citrate-coated) and GFP-AgBP protein-
functionalized AgNPs were added to each well and allowed to incubate for 24 hours at 37°C with 
5% CO2. To evaluate cellular viability, 10% v/v of AlamarBlue reagent (Life Technologies) was 
added to each treated well at the 22 hour time point, allowing cells to metabolize the reagent for 
about 2 hours prior to the 24 hour time point.  Both absorbance and fluorescence measurements 
were recorded, according to company protocol, to quantitatively assess cellular viability following 
24 hours of incubation with AgNP treatments. 
Cellular viability and cytotoxicity was also quantified using Live/Dead Viability/Cytotoxicity 
Kit (Life Technologies) to indicate intracellular esterase activity and plasma membrane integrity. 
Cells were plated and treated in 96-well plates following the same protocol as above. Following a 
24 hour incubation, cells were imaged using both brightfield and fluorescence imaging (BioTek 
Cytation3) to observe cell morphology and quantify cellular viability/cytotoxicity, respectively. 
Calcein-AM (green-fluorescent) stain identified healthy, viable cells whereas Ethidium 
Homodimer-1 (red-fluorescent) labeled the loss of membrane integrity of dead cells. Images were 
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taken for each well to determine the fluorescent contribution of the GFP-containing protein prior 
to Live/Dead staining and were subtracted for accurate staining activity analysis. Plates were 
treated such that 8 repeats of each AgNP concentration were averaged and compared to 
respective cell-only controls. A minimum of three plates were used for each concentration and 
treatment for analysis and normalized to respective plate controls. All results are presented as a 


















3. Chapter 3: Results and Discussion 
The schematic drawing shown in Figure 1 demonstrates the multifunctional fusion protein 
approach described in this work. Here, we developed a stable biointerface built upon self-
assembly of green fluorescence protein (GFP) engineered to include a silver binding peptide 
(AgBP) to produce multifunctional fusion protein that assembles on the surface of a silver 
nanoparticle. The AgBP provides a stable orientation for the GFP protein assembly on the AgNP 
surface as shown using localized surface plasmon resonance sensing. Next, AgNPs engineered 
with a biointerface, formed by the multifunctional fusion protein, are tested for antimicrobial activity 
over a range of concentrations and compared with the properties for widely accepted citrate-
coated AgNPs. Achieving a similar concentration range for antimicrobial activity of engineered 
biointerface AgNPs, cytotoxicity and cell viability assays were carried out to compare the 
outcomes with both citrate coated and nonspecific protein coated AgNPs.  
 
Figure 1. Schematics demonstrating the GFP-AgBP functionalization of silver 
nanoparticles (A), and the observed improvement in cellular viability in vitro (B) while 
maintaining the inherent antibacterial efficacy (C) at relatively low concentrations. 
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3.1 Characterization of Silver Nanoparticles 
The phenomenon of surface resonance was used to monitor AgNPs, where light spectral 
scanning at 300-700nm resulted in a strong absorption peak at around 410nm. The binding affinity 
and stability of the engineered bi-functional protein, GFP-AgBP, onto AgNPs was studied using 
localized surface plasmon resonance (LSPR) and compared against AgNPs incubated with GFP 
protein alone (no silver affinity tag) (Figure 2).  
LSPR spectra were taken to determine if protein binding was specific and stable following 
a wash step. AgNPs have unique interactions with light and display a characteristic optical spectra 
dependent upon their size and shape.[34, 79] Spectral shifts indicate an altered surface structure 
and size when AgNPs are successfully functionalized.[82] Silver nanoparticles did not result in 
agglomeration as an indication of instability of the interfaces at the reported concentration ranges 
and the nanoparticles sizes, they rather provided a distinct peak at the expected wavelength 
range. Greater adsorbed protein concentration resulted in a greater red-shift of the spectra, 
suggesting a slightly thicker nanoparticle size due to the relatively more stable protein layer 
formed at the surface.  Additionally, the distinct peaks observed for both the GFP-coated and 
GFP-AgBP-functionalized AgNPs indicate the particles remained discrete and did not 




Figure 2. Localized surface plasmon resonance (LSPR) spectra to confirm protein 
functionalization on the AgNPs. LSPR spectral peaks collected after 24 hour of incubation 
with GFP wild type protein (A) and engineered bifunctional protein GFP-AgBP (B). A red-
shift is observed as protein concentration increases. LSPR shifts following the 24 hour 
incubation and wash step to remove unbound (or weakly bound) protein indicate a 
sustained 2 nm shift for GFP (C) and a 7 nm shift for the GFP-AgBP spectra (D). GFP-AgBP 
is shown to provide a more stable and robust affinity AgNP coating when compared to the 
wild type protein alone. 
 
Following a 24 hour incubation, 40 nm AgNPs coated with either GFP or GFP-AgBP 
proteins revealed maximum red-shifts in the spectra of 9 nm and 19 nm, respectively as compared 
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to untreated (stock, citrate-coated) controls with an average spectral peak of 409 nm (Figure 
2a,b). Weakly bound and/or excess protein was then washed away with water. For concentrations 
less than 0.01 μM or less of proteins, a distinct peak was still observed following the wash step. 
LSPR spectra following the wash step displayed a spectra peak red-shift of only 2 nm and 7 nm 
for AgNPs coated with GFP and GFP-AgBP, respectively, as compared to untreated control 
samples (Figure 2c,d). The 7 nm shift observed for the GFP-AgBP-functionalized AgNPs indicates 
that the silver-binding affinity tag (AgBP) of our engineered fusion protein produces a stable and 
robust protein layer around the AgNPs as compared to the non-specific binding using GFP protein 
alone.  These observations are consistent with recent literature findings for AgNP functionalization 




Figure 3. Specific binding fit analysis for averaged LSPR shifts obtained at different protein 
concentrations for GFP-AgBP and GFP proteins. Dissociation constant (Kd) values were 
calculated as about 9.4 and 12.0 nM for AgNPs coated with either GFP-AgBP or GFP wild 
type protein, respectively. 
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LSPR experiments run at different protein concentration were used to calculate the Kd 
values (dissociation constant) to compare quantitatively the protein binding affinity onto the 
nanoparticle surface (Figure 3). Looking at specific saturation binding in this approach, we used 
a Langmuir adsorption model equation (Equation 1) to study the curve fit to determine the Kd. 





In Equation 1, the LSPR shift, y, was normalized from raw data by subtracting the peak 
wavelength of AgNPs alone (no protein) to determine the absolute shift in the peak absorbance 
following LSPR experiments at corresponding protein concentrations, x. The maximum LSPR shift 
at saturation, Bmax, is calculated through the curve fit analysis. The dissociation constant, Kd, 
represents the concentration needed to achieve a half-maximum binding at equilibrium, thus a 
smaller value indicates a greater binding affinity which was validated by the fact our GFP-AgBP 
protein had a smaller Kd value than GFP wild type at about 9.4 nM and 12 nM, respectively. This 
data shows that by attaching a small, silver-binding protein we can enhance our specific binding 
to the silver nanoparticle surfaces. 
 
3.2 Antimicrobial Efficacies of Silver Nanoparticles 
The antimicrobial efficiency of the functionalized AgNPs was studied using growth 
inhibition models and disc diffusion assays. Figure 4a shows a representative plate from the disc 
diffusion assay experiments. Clearly-observed zones of growth inhibition are seen the 40 nm 
AgNPs, as compared to a control (water only) disc. Figure 4b indicates a trend which suggests 
AgBP-GFP-functionalized nanoparticles may have an enhanced antimicrobial efficacy, although 
it was not statistically significant across all concentrations tested. The zones of inhibition were 
statistically similar for concentrations of 1.31, 2.63, and 5.25 μg/ml for the citrate-coated control 
and protein-functionalized samples (Figure 4b). At the lowest concentration, 0.66 μg/ml, the GFP-
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AgBP functionalized AgNPs showed a significantly larger zone of inhibition as compared to control 
nanoparticles. This difference can be attributed to the fact that the protein-coated nanoparticles 
boasted a stable biomimetic interface compared to the citrate-coated controls, allowing them to 
diffuse more easily from the loaded disc even at low AgNP concentrations. These data indicate 
that our protein-functionalized AgNPs potentially provide more potent and effective antimicrobial 
properties.  The measured zones of inhibition showed an increasing trend, but did not significantly 
change across concentrations of 1.31 μg/ml to 5.25 μg/ml. At higher concentrations, AgNPs have 
a greater potential to agglomerate, based upon spatial constraints in the treatment wells where 
the discs were pre-soaked in specified solutions and may get trapped or stuck to the polyethylene 
discs. Therefore, we attribute this plateau trend in inhibition zone at increasing AgNP 
concentrations to reduced diffusion capabilities for the concentrations of AgNPs we studied. 
 
Figure 4. S. mutans Agar Diffusion Assay. Representative image for observed zones of 
inhibition for the 2.63 μg/mL AgNP concentration (A) comparing GFP-AgBP-coated AgNP 
loaded discs (duplicate samples shown) and citrate-coated AgNPs discs with respect to a 
blank control. Graphical representation for measured inhibition zone diameter across four 
different concentrations studied to compare AgNPs coated with GFP-AgBP or citrate 
(stock AgNPs) (B). Ampicillin (10 μg/mL) was loaded onto a disc as a positive control. Data 
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trend indicates enhanced antimicrobial function with increasing AgNP concentration for 
both coatings. GFP-AgBP-coated silver nanoparticles have a significantly greater 
antimicrobial effect than citrate-coated AgNPs at the lowest concentration studies (0.66 
μg/mL). 
 
It is important to note that this engineered protein coating does not limit the natural 
antimicrobial efficacy of silver nanoparticles. Numerous reports in the literature utilizing a variety 
of chemically and covalently attached polymers or biomolecular moieties to functionalize and 
stabilize AgNPs, also showed changes and an overall reduction in antimicrobial efficacy due to 
the functionalization technique.[83-86] However, in light of recent findings regarding protein 
corona formation and altered size effects of AgNPs, the thickness and chemical properties 
imparted by the coatings can lead to significant changes in cellular cytotoxicity. Our protein self-
assembly technique provides a biologically tailored approach to functionalize nanoparticles with 
tunable and predictable surface properties while still maintaining the inherent antimicrobial 
functionality of AgNPs. 
 
3.3 In vitro Fibroblast Cellular Viability Model 
The effects of the protein-functionalized AgNPs were also studied in vitro using a fibroblast 
cell line to determine changes in cytotoxicity for mammalian cells subjected to those 
concentrations that demonstrated antimicrobial efficacy. Conflicting reports have shown a 
significant range of cytotoxic effects on cells in the presence of AgNPs in both in vitro and in vivo 
models.[20, 23, 67, 70, 71, 75-77, 85, 87, 88] Recent review articles describe these findings in 
detail with respect to AgNP size, shape, surface functionalization, concentration, and stability, 
among other properties.[18, 20, 25, 34, 47, 49, 67] Our studies are conducted with 40 nm AgNPs, 
a size shown to be small enough to provide antimicrobial efficacy. However in a variety of studies, 
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their size was also considered to be within a range to mitigate cytotoxic effects in cells.[71] The 
concentration range selected for our study was based upon recent studies and the antimicrobial 
assays we performed. The maximum AgNP concentration we studied, 5.25 μg/ml, is notably lower 
compared to many literature reports.[18, 22, 71, 77, 83] We attribute this favorable outcome to 
our novel protein self-assembly AgNP functionalization technique which offers enhanced stability 
without significantly altering AgNP size. Greater stability allows for maintaining or increasing their 
antimicrobial properties, while provided the added benefit of reducing their cytotoxic effects. 
We followed the morphological changes for the NIH/3T3 fibroblast cells by bright-field 
imaging following a 24 hour treatment with functionalized and control (citrate-coated) AgNPs. 
Adherent cells were imaged prior to treatment to ensure uniform confluency and morphology 
across the plates. A representative image is provided in Figure 5 which displays the brightfield 
image for a cells-only control well (sham treated, no AgNPs) following a 24 hour incubation. 
 
Figure 5. Brightfield imaging of the NIH/3T3 fibroblast cells control (no AgNPs) following a 
24 hour incubation. Image is shown at 20X magnification; scale bar represents 100μm. 
 
The morphological changes in the cells following the 24 hour incubation with 0.66 and 
1.31 μg/mL citrate and GFP-AgBP-coated AgNPs treatments are shown in Figure 6. These 
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images can be directly compared to Figure 5 (cells-only control) as well as the higher 
concentrations of 2.63 and 5.25 μg/mL coated-AgNPs (Figure 7). 
 
Figure 6. Representative brightfield images of the NIH/3T3 fibroblast cells treated with 
GFP-AgBP- or citrate-coated AgNPs at concentrations of 0.66 and 1.31 μg/mL. Following a 
24 hour incubation, the cells appear relatively healthy for the lowest concentration (0.66 
μg/mL) for both treatments as compared to the cells-only control shown in Figure 5. 
However, as AgNP concentration is increased to 1.31 μg/mL, cells appear to have an 
altered morphology and begin to detatch more significantly in the citrate-coated AgNPs as 
compared to the GFP-AgBP-coated AgNPs. Images are shown at 20X magnification; scale 




Figure 7. Brightfield imaging of the NIH/3T3 fibroblast cells treated with GFP-AgBP-coated 
(bottom) or citrate-coated (top) AgNPs at concentrations of 2.63 and 5.25 μg/mL. Following 
a 24 hour incubation, the cells appear less elongated and are seen to detach as AgNP 
concentration is increased (lower concentrations and control cells are shown in Figures 6 
and 5, respectively). The morphological effects appear significantly less severe for GFP-
AgBP-coated AgNPs as compared to stock AgNPs at the concentrations shown. Images 
are shown at 20X magnification; scale bar represents 100μm 
 
In all concentrations, cells subjected to the stock, citrate-coated nanoparticles appeared 
to have a less-healthy cell morphology, as compared to cell treated with respective concentrations 
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of GFP-AgBP protein-coated AgNPs. As expected, cells appeared more viable and healthy at the 
lower AgNP concentrations. The number of adherent cells still remaining in each well was also 
concentration dependent, suggesting that the higher concentrations were more cytotoxic leading 
to an increase in cellular detachment due to their significantly reduced viability. 
 
 
Figure 8. Cell viability of NIH/3T3 fibroblast cells exposed to increasing concentrations of 
AgNPs that are coated with either GFP-AgBP or citrate (control). There is a decreasing 
trend for cellular viability, measured by AlamarBlue fluorescence activity, as AgNP 
concentrations increase. Cells incubated with AgNPs functionalized with GFP-AgBP 
maintain a significantly higher cellular viability compared to cells exposed to citrate-





In parallel, cellular viability was studied using two independent methods. The Live/Dead 
staining technique uses a green versus red fluorescent imaging to indicate cell viability and 
cytotoxicity, respectively. Because our engineered fusion protein featured GFP, each plate prior 
to Live/Dead staining was imaged and the fluorescent contribution of our GFP protein subtracted 
from the live-dead assay. Moreover, to confirm cellular viability, parallel studies were performed 
where treated cells were subjected to the AlamarBlue viability assay. Figure 8 shows average 
fluorescence intensity measurements from AlamarBlue treated wells. A concentration-dependent 
decrease in cellular viability was observed with increasing AgNP concentrations for both the 
citrate-coated and GFP-AgBP functionalized nanoparticle treatments. Further, we observed a 
statistically significant improvement in cellular viability for cells treated with protein-functionalized 
AgNPs as compared to stock, citrate-coated AgNPs at concentrations of 1.31, 2.63, and 5.25 
μg/ml.  
Comparable viability results were observed for treated cells analyzed using Live/Dead 
staining methods. Representative Live/Dead staining images shown in Figures 9 and 10 
demonstrate the improved cellular viability and reduced cytotoxicity for protein-functionalized 
AgNPs as compared to citrate-coated controls at all AgNP concentrations. NIH/3T3 cells treated 
with GFP-AgBP-functionalized AgNPs measured greater viability and enhanced surface coverage 
more similar to the cell-only (untreated) control wells compared to citrate-coated nanoparticles at 
equal concentrations. Red fluorescent intensity, which indicates compromised membrane 
integrity and increasing cytotoxicity, increased with greater AgNP concentrations. However, cells 
treated with the protein-stabilized AgNPs show a significant reduction in cytotoxic activity at each 
concentration when compared to citrate-coated AgNP controls. The enhanced viability of cells 
exposed to GFP-AgBP-stabilized nanoparticles, as indicated by the green fluorescence intensity, 
demonstrates a clear dependence on AgNP surface functionalization for AgNPs of the same size 





Figure 9. Representative fluorescence images of the NIH/3T3 fibroblast cells treated with 
GFP-AgBP- or citrate-coated AgNPs at 0.66 and 1.31 μg/mL concentrations by Live/Dead 
staining. Following a 24 hour incubation with AgNP treatments, viable cells are identified 
by their green stain and cellular cytotoxicity is indicated by red stain. Protein-
functionalized AgNPs appear to maintain a significantly greater viability throughout 
increased concentrations as compared to cells treated with respective citrate-coated 







Figure 10. Representative fluorescence images of the NIH/3T3 fibroblast cells following a 
24 hour treatment with either GFP-AgBP- or citrate-coated AgNPs at 2.63 and 5.25 μg/mL 
concentrations by Live/Dead staining. Cellular viability (green stain) reduces as AgNP 
concentration is increased (lower concentrations shown in Figure 9). However, protein-
functionalized AgNPs maintain a greater viability throughout increased concentrations as 
compared to citrate-coated AgNPs. Cytotoxicity, indicated by the red fluorescence, was 
significantly greater (measured as a ratio to the number of viable cells/well) with increasing 
concentrations for citrate-coated compared to GFP-AgBP-coated AgNPs. Images are 




In this study, functionalized AgNPs were demonstrated to provide enhanced stability and 
reduced cytotoxic effects while still maintaining bactericidal efficiency. Our proposed approach 
using a peptide with specific inorganic-binding affinity offers the potential to engineer unique 
fusion proteins to provide tunable and predictable properties at the nanoparticle surface for 
enhanced biomaterial design toward reducing the burden of infection-associated implant failure 


















4. Chapter 4: Conclusions 
4.1 Conclusions 
While studying biological interactions with the nanoscaled materials are extremely important to 
address their safety concern, these analyses are often still deficient for studies with silver 
nanoparticles. Silver nanoparticles offer an exceptional opportunity to combat infections and treat 
antibiotic resistant bacteria, but their widespread use has been limited because of unanswered 
questions regarding toxicity to host cells and the related protein complexes that create a corona 
on their surfaces. The protein corona confounds quantitative and qualitative analysis. One way to 
overcome these complex interactions may be to engineer the silver nanoparticle surface using 
biological self-assembly to provide a competitive advantage over other competitive absorption at 
the interface. Combinatorial-selected inorganic binding peptides may offer an opportunity to 
provide a relatively stable interface at the AgNP surfaces that better serves a biomedical 
application. Herein, we genetically engineered a silver binding peptide and used it to form a 
biointerface to stabilize the surface of AgNP. By providing the peptide tag to bind silver within the 
multifunctional protein complex we succeeded in creating a protein cage around the nanoparticle 
where the resulting interface may have a better chance to stand the complex ongoing biological 
interactions. GFP-AgBP fusion protein demonstrates its ability to bio-self-assemble onto AgNPs 
in a tunable, concentration-dependent manner and displays a strong binding stability. Our results 
showed that a low concentration of 40nm silver nanoparticles, stabilized with our engineered 
fusion protein, provide a local antibacterial efficacy at a suitably low concentration while mitigating 
the cytotoxicity and improving viability in a fibroblast cell model, in vitro. These results offer a one-
step, environmentally friendly, and biomimetic approach to nanoparticle functionalization to 
overcome biomaterial-associated infection or offer a management path to the treatment of biofilm 
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